Rapid Dose Therapeutics Corp · CSE:DOSE
Rapid Dose Therapeutics — Investor Presentation (May 2019)
26 slides from Rapid Dose Therapeutics's investor presentation, May 2019
Slide 1: Corporate Presentation May 2019
CORPORATE PRESENTATION I MAY 2019 CSE: DOSE
Slide 2: Disclaimer
1 Disclaimer This documentation is a presentation (the “Corporate Presentation”) of general background information about the current activities of Rapid Dose Therapeutics (RDT) Canada Inc. (“RDT”) as of March 7, 2019. It is information in a summary form and does not purport to be complete. It is not
Slide 3: At a glance
2 At a glance Founded: May 3, 2017 Number of employees: 15 Publicly Traded: as of December 17, 2018 Ticker symbol: CSE:DOSE Shares Issued & Outstanding: 75,121,327 shares Warrants outstanding: 740,000 @ .50 cents (expiry as of May 17, 2019 ) Share Fully Diluted: 75,861,327 (Escrowed shares 49,310,83
Slide 4: Experienced management team
3 Experienced management team Mark Upsdell Jason Lewis Ian Fodie Chief Executive Officer SVP, Business Development Chief Financial Officer • Former Director, Global Strategy • An entrepreneurial executive with • CA from New Zealand Institute and Planning, CISCO +28 years of hands-on expertise • Prev
Slide 5: Building a global brand
4 Building a global brand Game Changing Delivery Rapid Dose Therapeutics, RDT, is a Canadian med-tech company providing a Managed Strip Service Program which enables proprietary drug delivery technologies designed to improve patient and consumer outcomes. RDT provides a turnkey service program for p
Slide 6: RDT verticals
5 RDT verticals RDT has three business divisions — delivering health and therapeutic applications. Over the Counter (OTC) Cannabis Pharmaceutical Nutraceuticals OTC product portfolio • QuickStrip™ • Branded drug (NPN, Health Canada medical and manufacturers seeking approved) recreational markets alt
Slide 7: Addressing the cannabis market
6 Addressing the cannabis market Quick, Convenient, Precise, Discreet™ RDT’s proprietary delivery system and trademarked brand QuickStrip™ transforms how QuickStrip™ precisely delivers active pharmaceutical, nutraceuticals Ingredients using an orally dissolvable strip and cannabis are consumed. to d
Slide 8: RDT QuickStrip lifestyle nutraceuticals
7 RDT QuickStrip™ lifestyle nutraceuticals Over the Counter (OTC) QuickStrip™ product portfolio (NPN, Health Canada approved) Distribution and e-commerce VITAMIN B12 SLEEP CSE: DOSE
Slide 9: Company milestones
8 Company milestones Definitive contract Rapid Dose Definitive contract signed with agreement Therapeutics Inc. signed with agreement with Aphria Canada listed on the with Aphria Germany CSE:DOSE Definitive contract Definitive contract Definitive contract signed with Chemesis signed with Flower One
Slide 10: Company milestones
9 Company milestones Top Ten New Product awarded by Grocery Patents pending Fourteen Innovation Canada in US and Canada trademarks filed in (GIC) for non-food Canada and the USA category QuickStrip™ available Expansion of operations Ten patents in for retail in hotel for a further 35,000 process of
Slide 11: Research & development
10 Research & development B12 Researching polymer EEG & behavioural Case Study of thin film technology study underway with B12 for IBS for oil-based UNLV with QuickStrip™ with major medical therapeutics delivery delivery system institution in Canada Case study delivering Development of methods Case
Slide 12: Cannabis recurring revenue business model
11 Cannabis recurring revenue business model RDT charges a service fee to licensed cannabis producers and growers globally, for production of RDT’s proprietary QuickStrip™ technology under a Managed Strip Service Agreement (MSSA) Minimum QTRLY production payments MSSA MSSA After production exceeds m
Slide 13: Financial impact of MSS Agreements
12 Financial impact of MSS Agreements RDT continues to perform The signed MSS agreements provide: under these signed MSS agreements. With • Initial signing fees, installation internal testing of production • Commissioning fees systems nearing completion, RDT has scheduled the delivery of five • Per
Slide 14: Canadian licensed manufacturer/reseller
13 Canadian licensed manufacturer/reseller Aphria secured $5.4MM private placement with RDT 7.2MM shares at $0.75 • Research • High-quality genetics & development • Expert Personnel • Clinical studies • Best practices • Manufacturing • Registered patient network • Marketing & sales • Marketing & sal
Slide 15: Germany licensed manufacturing/reseller
14 Germany licensed manufacturing/reseller Granted rights to license, manufacture, distribute and sell RDT’s QuickStrip™ technology to the German cannabis market • RDT and Aphria’s agreement will support • Germany has a population of 82 million rapid global expansion of the QuickStrip™ people — a po
Slide 16: Nevada manufacturing/reseller
15 Nevada manufacturing/reseller Granted license to manufacture, distribute and sell QuickStrip™ delivery technology for the cannabis market in Nevada. Nevada is one of • Flower One is the largest cannabis the most lucrative cultivation greenhouse in Nevada at 400,000 cannabis markets in square feet
Slide 17: Nevada cannabis market potential
16 Nevada cannabis market potential Nevada’s legal cannabis market (US$ in Millions) Based on Colorado YoY Growth Rate 1200 1144.4 995.2 1000 800 754.1 600 529.9 400 200 0 2018A 2019E 2020E 2021E Nevada 1 st Year Revenue 2018FY Estimate based on Colorado YoY In Colarado 3-year CAGR In Nevada 29.3 52
Slide 18: California licensed manufacturer/reseller
17 California licensed manufacturer/reseller With nearly 40 million residents and more than a million medical marijuana patients, California’s market represents about a third of the North American cannabis market. Estimated cannabis California sales: $5.1B $25B 2019 2026 • Established networks and c
Slide 19: Puerto Rico licensed manufacturer/reseller
18 Puerto Rico licensed manufacturer/reseller Puerto Rico public health department anticipates registration of 100,000 registered patients by end of 2019.2 Legalized medical cannabis for qualifying health conditions in 2015, allows the use of medical cannabis derivatives. Health Conditions include H
Slide 20: Thrive White Label Agreement (WLM)
19 Thrive White Label Agreement (WLM) This WLM agreement with Thrive RDT has signed a Memorandum of Understanding will maximize the use of the RDT’s (MOU) with Thrive Cannabis to sell white label oral production capacity — while enabling thin film strips with RDT’s proprietary QuickStrip™ Thrive, an
Slide 21: Global footprint
20 Global footprint CANADA WIDE EUROPE Germany, England, Netherlands, Poland USA Italy, Malta : CALIFORNIA PUERTO RICO AFRICA AUSTRALIA Lesotho SOUTH AMERICA Columbia, Brazil Argentina, Peru CSE: DOSE
Slide 22: Global market outlook
21 Global market outlook CBD The cannabidiol (CBD) Cannabis market is projected to grow 8x over the next 3 year from $202 million to Total size of the global $3B in 20212 cannabis market is estimated to reach $32B by 2022 $57B by 20271 Supplements Global dietary supplements market predicted to grow
Slide 23: In the news
22 In the news CSE: DOSE
Slide 24: Appendix
Appendix
Slide 25: Corporate video
24 Corporate video
Slide 26: Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics Corp. 1121 Walkers Line Burlington ON L7N 2G4 P: 1 416.477.1052 For inquiries: Ali Mahdavi Managing Director Spinnaker Capital Markets Inc. am@spinnakercmi.com (416) 962-3300 CSE: DOSE
Rapid Dose Therapeutics — Investor Presentation (May 2019) on 6ix